HIT Consultant May 4, 2021
Jasmine Pennic

What You Should Know:

– Today, PhysIQ Inc. announced its partnership with Johns Hopkins University, Duke University and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), to support a clinical trial to evaluate products for early treatment and post-exposure treatment of COVID-19. The 18-month study will assess disease progression and provide early indication of infection. This DOD-funded initiative will assess the role of continuous biosensor data and artificial intelligence in addressing the COVID-19 pandemic.

– Confirmed COVID-19 positive individuals and patients at high risk of exposure will wear a clinical-grade biosensor that continuously streams data to PhysIQ’s pinpointIQTM platform where advanced FDA-cleared analytics will process the raw biosensor data. In addition to capturing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients
23andMine: CEO Wojcicki aims to take genetics company private

Share This Article